1. Inflammation/Immunology

Inflammation/Immunology

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-12238G
    IWR-1 (GMP) 1127442-82-3 98%
    IWR-1 (IWR-1-endo) (GMP) is the IWR-1 (HY-12238) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis.
    IWR-1 (GMP)
  • HY-122437
    Quinuronium disulfate 135-14-8 98%
    Quinuronium disulfate, a babesicidal agent, possesses anticholinesterase activity.
    Quinuronium disulfate
  • HY-122483
    Diethyl pyimDC 1821370-64-2 98%
    iethyl pyimDC is a collagen prolyl 4-hydroxylase (CP4H1) inhibitor inhibitor with the IC50 of 2.6μM. Diethyl pyimDC can be used for study of antifibrotic and antimetastatic.
    Diethyl pyimDC
  • HY-122518
    8-Deazafolic acid 51989-25-4 98%
    8-Deazafolic acid is an antimicrobial drug for the folate-dependent bacteria, Streptococcus faecium (ATCC 8043) and Lactobacillus casei (ATCC 74691). 8-Deazafolic acid has activity against lymphoid leukemia L1210 in mice.
    8-Deazafolic acid
  • HY-122521
    Sootepin D 1154518-97-4 98%
    Sootepin D (compound 6), a triterpene from the apical bud of Gardenia sootepensis, inhibits TNF-α-induced NF-κB activity with an IC50 of 8.3μM. Sootepin D has anti-inflammatory activity.
    Sootepin D
  • HY-122542
    PPACK 71142-71-7 98%
    PPACK is a potent, peptidic inhibitor targeting thrombin and granzyme GZMK. PPACK specifically blocks the activities of thrombin and GZMK, thereby inhibiting thrombin-mediated PAR-1 cleavage, as well as downstream inflammatory and procoagulant signaling pathways. Through stabilizing IκB proteins, blocking NF-κB activation and reducing systemic levels of proinflammatory/procoagulant biomarkers, PPACK exerts multiple effects including anti-inflammatory, antithrombotic, barrier repair, and inhibition of atherosclerotic plaque progression. PPACK binds to platelets without interference from kininogen, effectively limiting acute thrombus growth and reducing eosinophil infiltration and goblet cell hyperplasia in asthma models. PPACK is an important tool molecule for investigating the mechanisms of atherosclerosis, asthma and related thromboinflammatory diseases.
    PPACK
  • HY-122565
    GSK-2239633 2181665-31-4 98%
    GSK-2239633 is an indazole arylsulfonamide-based CCR4 antagonist. GSK-2239633 is applicable to research related to asthma.
    GSK-2239633
  • HY-122584
    iNOs-IN-7 268730-08-1 98%
    iNOs-IN-7 (example 4) is an inducible nitric oxide synthase (NOS) inhibitor. iNOs-IN-7 can be used for the study of inflammatory disease and pain.
    iNOs-IN-7
  • HY-122655
    HMCEF 2002363-68-8 98%
    HMCEF is an orally active P-selectin inhibitor and inhibits P-selectin expression. HMCEF blocks the interaction between P-selectin and natural ligands, such as PSGL-1. HMCEF inhibits thrombosis and inflammation in mice.
    HMCEF
  • HY-122692
    TRPV4/TRPA1-IN-1 1532515-60-8 98%
    TRPV4/TRPA1-IN-1 is a TRPV4/TRPA1 inhibitor that suppresses TRPV4/TRPA1-mediated calcium influx. TRPV4/TRPA1-IN-1 alleviates pain behaviors in a mouse trigeminal stimulation pain model and inhibits inflammation and pain-related behaviors in a mouse acute pancreatitis model. TRPV4/TRPA1-IN-1 can be used in research on acute pancreatitis.
    TRPV4/TRPA1-IN-1
  • HY-122704
    Surfen 3811-56-1 98%
    Surfen is a potent heparan sulfate antagonist. Surfen inhibits FGF2 binding and signal transduction. Surfen binds to glycosaminoglycans and reduces tau hyperphosphorylation. Surfen inhibits the activity of recombinant uronyl 2-O-sulfotransferase with an IC50 of approximately 2 μM. Surfen inhibits HSV-1 viral infection. Surfen inhibits neural differentiation, delays remyelination, and alleviates EAE.
    Surfen
  • HY-12270S
    T-5224-d8
    T-5224-d8 is the deuterium labeled T-5224 (HY-12270). T-5224 is a transcription factor c-Fos/activator protein (AP)-1 inhibitor with anti-inflammatory effects, which specifically inhibits the DNA binding activity of c-Fos/c-Jun without affecting other transcription factors. T-5224 inhibits the IL-1β-induced up-regulation of Mmp-3, Mmp-13 and Adamts-5 transcription.
    T-5224-d8
  • HY-122769
    Adapiprazine 57942-72-0 98%
    Adapiprazine is a methyl-replaced Prochlorperazine, which has immunosuppressive and anesthetic effects.
    Adapiprazine
  • HY-122772
    (-)-Integerrimine 480-79-5 98%
    (-)-Integerrimine, a pyrrolizidine alkaloid, has antiulcerogenic activity. (-)-Integerrimine is also a mutagenic and weakly clastogenic agent in Drosophila.
    (-)-Integerrimine
  • HY-122833
    FGFR3-IN-10 2833703-74-3 98%
    FGFR3-IN-10 is a FGFR3 inhibitor with superior selectivity for FGFR3 over FGFR1.FGFR3-IN-10 can be used for the research of cancer, systemic sclerosis, fibrosis, pulmonary fibrosis, achondroplasia, thanatophoric dysplasia, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Muenke syndrome.
    FGFR3-IN-10
  • HY-12288S
    Ozanimod-d6
    Ozanimod-d6 (RPC-1063-d6) is the deuterium labeled Ozanimod (HY-12288). Ozanimod (RPC-1063) is a CNS-penetrant sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod has modulate effect for hS1P1 and hS1P5 receptor with EC50s of 1.03 nM and 8.6 nM, respectively. Ozanimod can be used for the research of relapsing multiple sclerosis (MS).
    Ozanimod-d6
  • HY-12290A
    Arg-Gly-Asp-Ser TFA 98%
    Arg-Gly-Asp-Ser (TFA) is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser (TFA) directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.
    Arg-Gly-Asp-Ser TFA
  • HY-122916
    7-Acetyllycopsamine 73544-48-6 98%
    7-Acetyllycopsamine, a pyrrolizidine alkaloid, is a mild hepatotoxin. 7-Acetyllycopsamine can induce liver inflammation in mice.
    7-Acetyllycopsamine
  • HY-122953
    Daturaolone 41498-80-0 98%
    Daturaolone is a natural triterpenoid with anti-inflammatory and antinociceptive potentials. Daturaolone displays a COX-1 inhibitory activity.
    Daturaolone
  • HY-123013
    Y 9000 53944-40-4 98%
    Y 9000 is an orally active antiallergic and anti-inflammatory compound. Y 9000 targets mast cells, inhibits the release of allergic mediators, stimulates the adrenal glands, exhibits glucocorticoid-like activity, and reduces adrenal ascorbic acid content. Y 9000 inhibits IgE-mediated and IgG-mediated allergic reactions as well as active systemic anaphylaxis in mice. Y 9000 inhibits allergic wheezing in passively sensitized guinea pigs and protects against active systemic anaphylactic shock in mice. Y 9000 inhibits non-immune responses in rats, including dextran-induced histamine release, anaphylactoid reactions and paw swelling. Y 9000 can be used in the research of allergic diseases (asthma, allergic rhinitis, urticaria, etc.).
    Y 9000
Cat. No. Product Name / Synonyms Application Reactivity